PLP-E7

PLP-E7 is an experimental cancer vaccine utilizing the Protein-Like Polymer (PLP) nanoplatform to deliver the Human Papillomavirus (HPV) E7 peptide antigen. Developed at Northwestern University, the PLP platform uses ring-opening metathesis polymerization (ROMP) to create proteomimetic polymers that mimic protein structures while offering enhanced stability against enzymatic degradation. PLP-E7 is designed to elicit potent antigen-specific T cell responses by facilitating targeted delivery to antigen-presenting cells (APCs). The polymer backbone can be modified with cleavable disulfide linkages for intracellular release and can electrostatically couple with adjuvants like STING agonists (e.g., 2'3' cGAMP) to further boost immunogenicity. In preclinical models, PLP-E7 has demonstrated the ability to reduce tumor burden and increase survival in TC-1 tumor-bearing mice.

Other names

Protein-Like Polymer-E7E7-PLPE-7-PLPE 7-PLP